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Abstract
Background: Rheumatoid Arthritis (RA) is one of the most common autoimmune diseases, affecting approximately
1% of the UK adult population. Patients suffer considerable pain, stiffness and swelling and can sustain various
degrees of joint destruction, deformity, and significant functional decline. In addition, the economic burden due to
hospitalisation and loss of employment is considerable, with over 50% of patients being work-disabled within
10 years of diagnosis. Despite several biologic disease modifying anti-rheumatic drugs (bDMARD) now available,
there is a lack of data to guide biologic sequencing. In the UK, second-line biologic treatment is restricted to a
single option, rituximab. The aim of the SWITCH trial is to establish whether an alternative-mechanism-TNF-inhibitor
(TNFi) or abatacept are as effective as rituximab in patients with RA who have failed an initial TNFi drug.
Methods/Design: SWITCH is a pragmatic, phase IV, multi-centre, parallel-group design, open-label, randomised,
controlled trial (RCT) comparing alternative-mechanism-TNFi and abatacept with rituximab in patients with RA who
have failed an initial TNFi drug. Participants are randomised in a 1:1:1 ratio to receive alternative mechanism TNFi,
(monoclonal antibodies: infliximab, adalimumab, certolizumab or golimumab or the receptor fusion protein,
etanercept), abatacept or rituximab during the interventional phase (from randomisation up to week 48). Participants
are subsequently followed up to a maximum of 96 weeks, which constitutes the observational phase. The primary
objective is to establish whether an alternative-mechanism-TNFi or abatacept are non-inferior to rituximab in
terms of disease response at 24 weeks post randomisation. The secondary objectives include the comparison of
alternative-mechanism-TNFi and abatacept to rituximab in terms of disease response, quality of life, toxicity, safety and
structural and bone density outcomes over a 12-month period (48 weeks) and to evaluate the cost-effectiveness of
switching patients to alternative active therapies compared to current practice.
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Discussion: SWITCH is a well-designed trial in this therapeutic area that aims to develop a rational treatment algorithm
to potentially inform personalised treatment regimens (as opposed to switching all patients to only one available (and
possibly unsuccessful) therapy), which may lead to long-term improved patient outcomes and gains in population health.
Trial registration: UKCRN Portfolio ID: 12343; ISRCTN89222125; NCT01295151
Keywords: Rheumatoid arthritis, TNF-inhibitor, Rituximab, Abatacept, Non-responder, Biologics, Randomised clinical trial,
Cost-effectiveness
Background
Rheumatoid Arthritis (RA) is one of the most common
autoimmune diseases; a chronic, systemic, inflammatory
arthritis, affecting approximately 1% of the UK adult popu-
lation [1] and is the largest cause of treatable disability in
the Western world [2,3]. Patients suffer considerable pain,
stiffness and swelling and if not adequately controlled, sus-
tain various degrees of joint destruction, deformity, and
significant functional decline [3]. In addition to the impact
of RA on the individual, the health economic and societal
burden is considerable, due to hospitalisation and loss
of employment with over 50% of patients work-disabled
within 10 years of diagnosis [4].
RA is also associated with a significant increase in mor-
tality, up to three-fold compared to the general population
[5] with the standardised mortality rates (SMR) in severe
cases, described as comparable to Non-Hodgkin’s lym-
phoma, triple vessel coronary artery disease and cerebro-
vascular disease [6]. The increased mortality is largely due
to increased frequency of premature cardiovascular dis-
ease (CVD) [7], which constitutes up to 40% of mortality
in RA patients and is as high as that of patients with other
major CVD risk factors such as Type 2 diabetes mellitus
[8]. This appreciation has further highlighted the impor-
tance of ensuring optimal and effective disease control.
Expedient implementation of disease modifying anti-
rheumatic drug (DMARD) therapy is the cornerstone of
management of RA. Nevertheless, it has become clear that
poor response (even if initially effective) remains a feature
with most DMARDs over time. In addition, a high inci-
dence of toxicity has been observed with these drugs [9].
Such obstacles to therapy combined with data suggesting
limited alteration in long-term outcome even in those
showing response has argued for more effective thera-
peutic options [10].
This unmet clinical need fuelled research into RA,
which led to significant advances in our understanding
of RA by the 1990s, with an appreciation of the role of
excess pro-inflammatory cytokines, in particular tumour
necrosis factor (TNF) in driving RA pathogenesis [11].
Following in vitro and in vivo work, the most compel-
ling evidence for a key role for TNF-inhibitor (TNFi)
stemmed from studies where marked clinical benefit was
observed in patients with RA treated with chimeric
TNF-alpha monoclonal antibodies [12]. The subsequent
introduction of several costly but highly effective TNFi
therapies marked the start of a new era in biologic
DMARD (bDMARD) drug development for RA [13-15].
TNF-inhibitors
Cochrane reviews provide clear evidence that the licensed
TNFi drugs (etanercept, infliximab, adalimumab, certoli-
zumab and golimumab) produce better outcomes in RA
compared with placebo or treatment with conventional
DMARDs [16-19]. All these are in the same class of drug
i.e. TNFi, but differ in several respects:
i. Molecule type [infliximab, chimeric (mouse-human)
monoclonal antibody; adalimumab, humanised and
golimumab, fully human monoclonal antibody;
certolizumab, PEGylated Fab fragment of a
humanised monoclonal antibody to TNF and
etanercept, fusion protein];
ii. Target (etanercept binds both TNF-alpha and
another cytokine, lymphotoxin-alpha);
iii. Binding affinity to TNF [20];
iv. Mechanism of drug action [20-22];
v. Route of administration (all subcutaneous except for
infliximab);
vi. Frequency of administration.
Despite the extensive benefits of TNF-directed biologic
therapies, a significant proportion of RA patients fail to
achieve sufficient response [23]. Two broad approaches
can be employed to manage initial TNFi non-response;
switching to an alternative TNFi therapy or use of an-
other mechanism agent. Of the latter, rituximab, a B-cell
depleting therapy, abatacept, and more recently, toci-
lizumab, have been licensed, although only rituximab is
currently approved by the National Institute for Health
and Care Excellence (NICE) at the TNFi-failure stage [24].
Switching between TNF-inhibitors
Current NICE guidance does not permit switching to an
alternative TNFi as a second-line biologic therapy choice
unless rituximab +/− methotrexate is contraindicated.
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Several early phase, uncontrolled studies and an initial,
small, randomised study suggested benefit in switching
between TNFi agents [25-35]. A report of high ACR20
responses on an alternative TNFi agent in specific sub-
group of patients [27] also indicates the potential value
of and the need to explore this approach further. The ra-
tionale and argument for switching between different
TNFi drugs was strengthened by a large, randomised
industry-led efficacy study comparing golimumab with
placebo. This phase III study of 461 patients who had
previously received and either failed or were intolerant
to one or more TNFi were randomised to placebo, sub-
cutaneous golimumab 50 mg or 100 mg 4-weekly. Sig-
nificantly higher ACR20 response rates at week 14 were
observed in the 50 mg and 100 mg golimumab groups
compared to placebo group (35% and 38% versus 18%
respectively) [36].
A key benefit of the TNFi is their suitability in both
seropositive and seronegative disease [to rheumatoid
factor (RF) +/− anti-citrullinated peptide antibody
(ACPA)]. This is in contrast with data implying the in-
fluence of antibody status and response rates in patients
treated with rituximab (particularly at the TNFi-failure
stage, see below) due to its distinct target and rationale
for use (rituximab depletes the autoantibody producing
B-cells)[37,38]. It is therefore important not to prema-
turely discount an alternative TNFi drug as an effective
therapeutic option, particularly in the context of such
resistant and aggressive disease cohorts. In addition,
patients with RA may have a co-existing immune-
mediated inflammatory disease (for example, inflamma-
tory bowel disease, psoriasis) that would also be amenable
to treatment with a TNFi (with rituximab not as suitable
and potentially toxic) [36,39-42]. Having the option of
using a second TNFi in this scenario would be clinically
more appropriate than having to potentially consider two
different classes of bDMARDs.
Alternative bDMARD therapies
Industry-led efficacy studies have demonstrated benefits
of rituximab, abatacept and tocilizumab after TNFi fai-
lure [43-47] although only rituximab is NICE-approved
(and neither abatacept nor a TNFi has been compared to
rituximab). Rituximab, however, is not appropriate for
certain patients and may even lead to unpredictable
responses or toxicity [48], or failure to respond (up to a
third of patients). Furthermore, meta-analyses of rituxi-
mab suggests seronegative antibody status, seen in up to
25-30% of patients, appears to be associated with poorer
response, particularly in the TNFi-failure trial; although
this has not been formally tested [37,44,45,49,50]. Recent
data on abatacept from an observational registry also
suggests seropositive status may confer greater benefits
to abatacept therapy [51].
A Swiss observational study [52] comprised 116 patients
who had failed at least one TNFi agent and were switched
to either an alternative TNFi therapy or to one cycle of
rituximab with the results suggesting that rituximab was
the more favourable treatment option. Aside from the
small sample size, this retrospective study had several
other design limitations with outcome taken from diffe-
ring time-points and inclusion of all types of initial TNFi
failure; in addition it was neither controlled nor ran-
domised to treatment type. The observational studies
MIRAR and SWITCH-RA have also reported the use of
rituximab as a better strategy compared to an alternative
TNFi drug following insufficient response to a first TNFi
[53,54]. The collaborative CERRERA registry [55,56] has
also suggested utility of rituximab but in contrast to the
Swiss study, following TNFi toxicity as opposed to lack of
efficacy [57]. Other observational studies comparing alter-
native TNFi with other bDMARDs, such as abatacept and
tocilizumab as well as rituximab, also favour these therap-
ies over the use of alternative mechanism TNFi as second
line treatment [58-60]. These results have also been con-
solidated by recent RCTs (preliminary data) [61,62] and
meta-analyses, which have failed to demonstrate supe-
riority of one therapy over another [63], with European
recommendations also confirming all currently licensed
therapies as appropriate options [64].
It therefore remains unclear how best to utilise the alter-
native bDMARDs described above following initial TNFi
failure. It is apparent that no universally effective treat-
ment exists with the present approach, and clinicians
treating patients in the absence of sufficiently strong
data is unsatisfactory. The current reality of second-line
bDMARD restricted to a single option (rituximab) in the
UK seriously impedes effective management. This is par-
ticularly pertinent to patient sub-groups where alternative
licensed therapies may seem more appropriate (e.g. in
seronegative RA, concomitant immune mediated inflam-
matory diseases). This poses a significant problem to the
NHS and is in conflict with the patient agenda. Despite
several treatment options now being available, no good
quality head-to-head comparisons investigating the effi-
cacy of sequential biologic treatments have been con-
ducted to date.
The SWITCH trial aims to provide clear guidance to
clinicians. The results of this study will enable the deve-
lopment of a rational treatment algorithm and should
enable more judicious and cost-effective management; in
particular it will potentially allow personalised treatment
regimens as opposed to switching all patients to only
one available (and potentially unsuccessful) therapy, po-
tentially leading to long-term net-benefits and improved
patient outcomes.
Whilst more recent technology appraisal permits the
use of abatacept, a T-cell co-stimulation blockade agent,
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and tocilizumab, an interleukin-6 receptor monoclonal
antibody, as first-line biologic together with TNFi [65],
TNFi, remains the predominant first-line bDMARD cur-
rently prescribed in the UK [66].
Methods/Design
Trial aims and objectives
The general aim of the trial is to compare alternative-
mechanism TNFi to rituximab, and abatacept to rituximab
in terms of disease response, quality of life, cost-effective-
ness, toxicity and safety over a 12-month (48 weeks) period.
Each of the two comparisons (TNFi vs. rituximab and aba-
tacept vs. rituximab) is considered to be of interest inde-
pendently, and the trial aims to establish non-inferiority;
therefore no adjustments for multiple comparisons have
been planned.
Primary objective
To establish whether an alternative-mechanism-TNFi
or abatacept are non-inferior to rituximab in terms
of disease response at six months (24 weeks) post
randomisation.
Secondary objectives
 To compare alternative-mechanism-TNFi and
abatacept to rituximab in terms of disease
response, quality of life, toxicity, safety, structural
and bone density outcomes (in terms of plain
radiography and bone densitometry score) over a
12-month (48 weeks) period.
 To undertake an evaluation of the cost-effectiveness
of switching patients to an alternative-mechanism
TNFi, abatacept or rituximab.
Exploratory objectives
 To determine the optimal sequence of treatments
by assessing whether response to the second
treatment in patients with RA is related to the
initial failed TNFi (TNFi monoclonal or TNF
receptor fusion protein).
 To evaluate whether the response to the second
treatment (alternative mechanism TNFi, abatacept
or rituximab) is related to whether the patient
was a primary (no initial response) or secondary
(loss of an initial) response failure to their initial
TNFi.
 To ascertain whether seropositive and seronegative
(to rheumatoid factor +/− anti-citrullinated peptide
antibody) RA patients behave differently in their
response and disease outcome measures in the three
treatment arms, particularly in the comparisons
with rituximab.
Trial design
SWITCH is a pragmatic, phase IV, multi-centre, parallel-
group, open-label, RCT comparing alternative mecha-
nism TNFi with rituximab, and abatacept with rituximab
in a total of 477 patients with rheumatoid arthritis who
have failed an initial TNFi drug. Participants will be ran-
domised to receive one of the following for a maximum
of 48 weeks (interventional phase):
1) Alternative mechanism TNFi:
a) Etanercept if initial failure to a monoclonal
antibody (infliximab, adalimumab, certolizumab
or golimumab)
OR
b) Infliximab, adalimumab, certolizumab or
golimumab if initial failure to the receptor fusion
protein etanercept (choice of TNFi at
investigator’s discretion)
2) Abatacept
3) Rituximab
All participants will subsequently be followed up from
week 48 for a maximum of 96 weeks to the end of the
trial, which constitutes the observational phase (see
Figure 1).
Eligibility
The British Society of Rheumatology (BSR) provides
guidelines on the use of TNFi [67]. These guidelines in-
clude important exclusion criteria that are adhered to in
clinical practice. These will also be applied in this study.
The inclusion and exclusion criteria for randomisation
into this study are detailed in Table 1.
Recruitment
Participants will be recruited from multiple research sites
within the United Kingdom; some of the collaborating re-
search centres have been initially selected under the guid-
ance of the Arthritis Research UK’s Adult Inflammatory
Arthritis Clinical Study Group (AIA CSG). In addition,
potentially eligible patients may also be identified via
Participant Identification Centres (PICs). The identified
clinicians at these PICs will refer potential participants
to the research team based in one of the participating
research sites for assessment and possible recruitment to
the trial.
Patients will be approached during standard clinic
visits for management of their disease. Alternatively, pa-
tients identified by other means (such as waiting lists,
registries, review of case records) may be sent the perso-
nalised Switch Invitation letter inviting them to take
part. Patients will be provided with verbal and written
details about the trial (Participant Information Sheet and
Informed Consent Document). Patients will have as long
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Figure 1 Switch trial flow diagram.
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Table 1 Eligibility criteria for randomisation into the Switch trial
INCLUSION CRITERIA
1 Male and female subjects aged ≥18 years at the time of signing the Informed Consent Form.
2 Patients with a diagnosis of rheumatoid arthritis as per the ACR/EULAR 2010 classification criteria confirmed at least 24 weeks prior to the
screening visit.
3 Patients who have failed conventional DMARD therapy as per NICE/BSR Guidelines i.e. failure of at least 2 DMARDS including methotrexate.
4 Patients with persistent RA disease activity despite having been treated with a current initial TNFi agent for at least 12 weeks. Active RA defined
as*: a. Primary non-response: failing to improve DAS28 by > 1.2 or failing to achieve DAS28≤ 3.2 within the first 12 to 24 weeks of starting the
initial TNFi.
● This may include patients that have shown a reduction in DAS28 of >1.2 but still demonstrate unacceptably high disease activity in the
physician’s judgement with evidence of an overall DAS28 of ≥3.2.
OR
b. Secondary non-response: defined as inefficacy to first TNFi (having demonstrated prior satisfactory response) as per clinician judgement; with
intolerance not the reason for cessation of first TNFi.
5 Methotrexate dose stable for 4 weeks prior to the screening visit and to be continued for the duration of the study.
6 Patients on NSAIDs and/or corticosteroids (oral prednisolone not exceeding 10 mg daily) who have been on an unchanged regimen for at least
4 weeks prior to the screening visit and are expected to remain on a stable dose until the baseline assessments have been completed.
7 Provided written informed consent prior to any trial-specific procedures.
*These criteria are consistent with BSR guidelines
EXCLUSION CRITERIA
General
1 Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 52 weeks following randomisation.
Study Specific
2 Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter’s syndrome, psoriatic arthritis, systemic lupus
erythematosus, or any arthritis with onset prior to 16 years of age.
3 Patients receiving doses of prednisolone > 10 mg/day within the 4 weeks prior to the screening visit.
4 Patients receiving intra-articular or intra-muscular steroid injections within 4 weeks prior to the screening visit.
Excluded Previous or Concomitant Therapy:
5 Patients who have previously received more than 1 TNFi drug OR any other biological therapy for the treatment of RA.
6 Patients unable or unwilling to stop treatment with a prohibited DMARD (i.e. synthetic DMARD aside from MTX e.g. oral or injectable gold,
chloroquine, hydroxychloroquine, cyclosporine, azathioprine, leflunomide, sulphasalazine) prior to the start of protocol treatment.
7 Treatment with any investigational drug in the last 12 weeks prior to the start of protocol treatment.
Exclusions for general safety - These criteria should be considered in the context of BSR guidance [44].
8 Patients with other co-morbidity including acute, severe infections, uncontrolled diabetes, uncontrolled hypertension, unstable ischaemic heart
disease, moderate/severe heart failure (Class III/IV of the New York Heart Association (NYHA) functional classification system), active bowel disease,
active peptic ulcer disease, recent stroke (within 12 weeks before the screening visit), or any other condition which, in the opinion of the
investigator, would put the patient at risk to participate in the study or would make implementation of the protocol difficult.
9 Patients with any major episode of infection requiring hospitalization or treatment with IV antibiotics within 12 weeks of start of treatment
protocol or oral antibiotics within 4 weeks of start of protocol treatment.
10 Patients at significant risk of infection, which in the opinion of the investigator would put the patient at risk to participate in the study (e.g. leg
ulceration, indwelling urinary catheter, septic joint within 52 weeks (or ever if prosthetic joint still in situ)).
11 Patients with known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections including herpes zoster
(for tuberculosis and Hepatitis B and C see below), but excluding fungal infections of nail beds as per clinical judgement.
12 Patients with untreated active current or latent tuberculosis (TB). Patients should have been screened for latent TB (as per BSR guidelines) within
24 weeks prior to the screening visit and, if positive, treated following local practice guidelines prior to the start of protocol treatment.
13 Patients with active current hepatitis B and/or C infection. Patients should have been screened for hepatitis B and C within 24 weeks prior to the
screening visit and if positive, excluded from the study.
14 Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation.
15 Pregnancy, lactation or women of child-bearing potential (WCBP) unwilling to use an effective birth control measure whilst receiving treatment
and after the last dose of protocol treatment as indicated in the relevant Summary of Product Characteristics (SmPC)/Investigator Brochure (IB).
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as they need to consider participation. Assenting pa-
tients will be invited to provide informed, written con-
sent before being registered into the trial and formally
assessed for eligibility.
Consent to the switch trial BioBank
Patients who are eligible to take part in the trial will also
be eligible to have a number of biological samples (blood
and urine) taken for the Switch Trial BioBank. Participa-
tion will be discussed with patients at the same time as
discussing their participation in the main trial. Patients
who agree to have biological samples taken for the
Switch Trial BioBank will be asked to sign an additional
consent form.
Screening and registration
Following written informed consent and prior to any trial
related invasive or non-invasive procedures, patients will
be registered into the study. All patients will undergo a
screening assessment within 4 weeks prior to the baseline
assessments to determine eligibility for the study.
Randomisation
Following registration, confirmation of eligibility and
completion of baseline assessments and questionnaires,
participants will be randomised in a 1:1:1 ratio to receive
alternative mechanism TNFi, abatacept or rituximab.
Treatment group allocation will use minimisation in-
corporating a random element, via a computer-generated
programme, to ensure treatment groups are well-balanced
for: centre; disease duration (<5 years or ≥ 5 years); non-
response (primary or secondary); rheumatoid factor status
(RF seropositive or ACPA positive) or (RF seronegative
and ACPA negative)). Both registration and randomisation
will be performed centrally using an automated 24-hour
telephone system based at the Leeds Clinical Trials Re-
search Unit (CTRU).
Participating research sites will be required to com-
plete a log of all patients over the age of 18 with RA
who have failed an initial TNFi agent and have been
considered for the trial, but not registered for screening
or randomised, either because they are ineligible or
because they decline participation.
Trial Intervention
Treatment will be administered in the three arms as de-
tailed in Table 2. Participants will receive the randomised
treatment for a minimum of 24 weeks, after which, 24-
week responders will continue treatment to 48 weeks.
After week 48, the randomised treatment may be conti-
nued if response is maintained and local practice/guide-
lines permits on-going use of a non-NICE approved
treatment if relevant. The observational phase constitutes
the follow up period from week 49 to the end of the trial,
with a maximum follow-up duration to week 96. The
duration of the observational phase will therefore vary
amongst the participants. After the observational phase
participants will return to NHS routine care.
Participants who, in the investigator’s opinion, demon-
strate an unacceptably high level of disease activity prior
to week 24 may discontinue treatment if clinically indi-
cated. These participants will be followed up as part of
the observational phase of the trial. The DAS28 score
[68] obtained at week 24 will be used for the primary
endpoint.
Assessments, samples and data collection
All protocol-required assessments will be recorded on
paper case report forms at each site.
The trial visits are structured as detailed below (see
also Figures 2, 3 & 4):
 Screening visit: All patients will undergo screening
within 4 weeks prior to the baseline assessment.
 Baseline visit: Baseline assessments are to be
performed to confirm that the participant is still
eligible for the study and to undertake
randomisation to study treatment.
Table 1 Eligibility criteria for randomisation into the Switch trial (Continued)
16 Men whose partners are of child-bearing potential but who are unwilling to use an effective birth control measure whilst receiving treatment
and after the last dose of protocol treatment as indicated in the relevant SmPC/IB.
Laboratory value exclusions
17 Patients with known significantly impaired bone marrow function as for example significant anaemia, leukopaenia, neutropaenia or
thrombocytopaenia as shown by the following laboratory values at the time of the screening visit:
● Haemoglobin < 8.5 g/dl
● Platelet count < 100 x 109/L
● White blood cell count < 2.0 x 109/L
● Neutrophil count < 1 x 109/L
18 Patients with known severe hypoproteinaemia at the time of the screening visit, e.g. in nephrotic syndrome or impaired renal function, as
shown by:
● Serum creatinine > 150 umol/L
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 Clinical assessment visits: Randomised participants
attend these visits as part of the interventional
(weeks 12, 24, 36 and 48) and the observational
(weeks 60, 72, 84 and 96) phases of the study.
 Infusion visits: Participants allocated to Rituximab
or Infliximab will undergo additional standard
assessments for safety purposes on the infusion
dates.
 Biological samples from participants consenting to
the SWITCH Trial BioBank sub-study will be
collected prior to commencement of trial treatment
and at weeks 2/4, 12, 24, 48 and at the time of
early discontinuation if it occurs outside of these
time-points (see Figures 2, 3 & 4). The samples will
be sent to a central Switch Trial Biobank. These
samples will be used for a range of studies of direct
relevance to the treatment of RA.
Outcomes
The primary outcome is the change in Disease Activity
Score 28 (DAS28) [68] at 6 months (24 weeks). Secondary
outcomes at weeks 12, 24, 36 and 48 are: the DAS28 score
and the proportion of participants who achieve a reduction
in DAS28 score of greater than 1.2 from baseline, Low
Disease Activity Score (LDAS) rate [69] and remission rate
[70], EULAR (European League Against Rheumatism) and
ACR (American College of Rheumatology) response scores
[69,71], changes in scores and proportion of participants
in each category of the Clinical Disease Activity Index
(CDAI) [72] and Simplified Disease Activity Index (SDAI)
[73], the proportion of participants that achieve ACR/
EULAR Boolean remission rate [70] at each time-point.
The outcomes relating to quality of life at weeks 12, 24, 36
and 48 are: the RA Quality of Life (RAQoL)[74], the
Hospital Anxiety and Depression Scale (HADS)[75], and
the Health Assessment Questionnaire Disability Index
(HAQ-DI) [76]; the HAQ-DI will also be evaluated at
weeks 60, 72, 84 and 96. The outcomes required for the
cost-effectiveness analysis and collected at weeks 12, 24,
36 and 48 are: EQ-5D [77], Health Utilities Index (HUI)
[78], Health and Social Care Use & Expenditure due to
Rheumatoid Arthritis [79]. EQ-5D and Health Utilities
Index will also be evaluated at weeks 60, 72, 84 and 96.
Further outcomes correspond to safety (adverse events
and reactions) and toxicity (requiring cessation of treat-
ment) reported throughout the duration of the trial treat-
ment (up to week 48). In addition, outcomes related to
radiographic measures at week 48 will be: changes in
Genant-Sharp scores [80] of hands and feet, and bone
densitometry T-scores of neck of femur and lumbar spine.
Sample size
A total of 477 participants will be recruited to this study.
A total of 429 evaluable participants are required to have
Table 2 The three treatment arms of the Switch trial
TREATMENT ARM TREATMENT DESCRIPTION
Rituximab Single dose of 1 g as an intravenous infusion to be administered at days 0 (week 0) and 15
(week 2; +5 days).
In line with standard practice, a participant who loses an initial 6 month (week 24) response
as per NICE guidance may receive a further cycle of rituximab after a minimum of 6 months
following the first dose. The second cycle of rituximab will be given at a dose of 1 g x 2
intravenous infusions will be administered at a 2-week interval (+5 days).
Abatacept Abatacept solution for subcutaneous injection: 125 mg/syringe (125 mg/mL). Abatacept will
be given at a dose of 125 mg by subcutaneous injection at week 0 and once weekly
thereafter for a minimum of 24 weeks.
Supplied by Bristol-Myers Squibb free of charge. Trial supplies to be ordered by individual
sites which will be responsible for ring-fencing abatacept upon receipt.
Alternative mechanism anti-TNF Etanercept Single dose of 50 mg etanercept by subcutaneous injection weekly for a minimum of
24 weeks (unless not tolerated).
Adalimumab Single dose of 40 mg adalimumab by subcutaneous injection every 2 weeks for a minimum
of 24 weeks (unless not tolerated).
Infliximab Infliximab will be given at a dose of 3 mg/kg per intravenous infusion, administered on a
day-case unit or equivalent. The intravenous infusions will be administered at week 0, 2
(+/− 2 days), 6 (+/− 2 days) and then 8-weekly thereafter (+/− 7 days) for a minimum of
24 weeks.
Certolizumab Pegol Single dose of 400 mg by subcutaneous injection at weeks 0, 2, 4 and then at a dose of
200 mg every 2 weeks thereafter for a minimum of 24 weeks.
Certolizumab pegol will be available free of charge for the first 12 weeks of protocol
treatment if supplied by UCB Pharma through their RA Patient Access Scheme.
Golimumab Single dose of 50 mg by subcutaneous injection every 2 weeks for a minimum of 24 weeks.
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80% power for demonstrating non- inferiority of either
abatacept or alternative mechanism TNFi to rituximab
at the 5% significance level. A total of 143 evaluable
participants in each treatment group will ensure that
the lower limit of the two-sided 95% confidence interval
for the true difference in DAS28 (abatacept/alternative
mechanism TNFi – rituximab) lies above −0.6 units, as-
suming no difference between treatment groups and a
between-participant standard deviation of 1.8 units [44].
Allowing for a loss to follow-up of 10%, a total of 477
participants will be recruited.
Statistical analysis
All analyses will be conducted on the Intention-To-
Treat (ITT) population, where patients will be included
according to the treatment to which they were allocated
at randomisation. A Per-Protocol (PP) population will
also be defined for the non-inferiority analyses, which
will exclude participants who violate the protocol or fail
to comply with the required treatment regime. Non-
inferiority will need to be demonstrated in both ITT and
PP populations in order to infer non-inferiority. All for-
mal analyses will be carried out at a 2-sided 5% level of
significance.
An interim analysis will be conducted after 239 par-
ticipants have completed 24 weeks of follow-up to
allow for early stopping of a treatment arm; specifically
if either abatacept or alternative mechanism TNFi is
shown to be inferior to rituximab, which will be based
on the confidence interval excluding the value zero.
Primary outcome analyses
Multiple-variable linear regression will be used to com-
pare the alternative mechanism TNFi and abatacept to ri-
tuximab with the dependent variable, the change in
DAS28 at 6 months (24 weeks), and the minimisation fac-
tors (centre, disease duration (<5 years, ≥5 years), rheu-
matoid factor status, primary/secondary non-response)
and the baseline value of DAS28 included as independent
variables. The mean treatment differences, 95% CIs and
p-values from this analysis will provide the main compari-
sons for each treatment group with rituximab.
Secondary outcome analyses
Alternative mechanism TNFi and abatacept will be com-
pared to rituximab at 12, 24, 36 and 48 weeks using the
following methods:
Figure 2 Schedule of events for rituximab.
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 DAS28: Multi-level repeated measures analysis,
including minimisation factors and baseline DAS28
in addition to treatment.
 Markers of achieving DAS28 reduction of greater
than 1.2 without toxicity, DAS28 LDAS and
remission rates, ACR/EULAR Boolean remission
and ACR response rates: Binary logistic regression
analysis including the minimisation factors and
baseline DAS28 in addition to treatment.
EULAR response scores, SDAI and CDAI scores:
Ordinal logistic regression analysis including the
minimisation factors and baseline DAS28 in addition
to treatment.
RAQoL, HADS, HAQ-DI: Linear regression analysis
will fitted to the change in QoL scores between
baseline and 6 months including the minimisation
factors and baseline DAS28 in addition to
treatment.
 Safety and Toxicity: The proportion of participants
experiencing toxicity will be summarised by
treatment received. Adverse events (including
serious adverse events (SAEs), serious suspected
adverse reactions and suspected unexpected serious
adverse events) will be summarised by treatment
group and the relationship between events and
study treatment or underlying RA will be assessed.
Expected SAEs common to all treatments include
injection site/infusion reactions, blood dyscrasias,
serious infections, toxic epidermal necrolysis,
Stevens-Johnson syndrome, pulmonary fibrosis,
renal failure, neurological impairment, and new
autoimmunity. In addition, intolerance to protocol
treatment will be summarised by treatment received.
Exploratory analyses
To determine if there is a differential response according
to TNFi type (monoclonal antibody or fusion protein)
initially failed, a linear regression model will be fitted to
DAS28 at 24 weeks including baseline DAS28, type of
TNFi initially received and minimisation factors as inde-
pendent variables. To determine if there is a differential
treatment effect according to primary and secondary
failure to initial TNFi received, a linear regression model
will be fitted to DAS28 at 24 weeks on baseline DAS28,
treatment, primary/secondary failure, remaining mini-
misation factors, and an interaction term between treat-
ment and type of failure. Finally a linear regression
model will be fitted to DAS28 at 24 weeks including
Figure 3 Schedule of events for infliximab.
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baseline DAS28, treatment, rheumatoid factor status,
remaining minimisation factors, and an interaction term
between treatment and rheumatoid factor status in order
to assess if there is a differential treatment response bet-
ween seropositive and seronegative patients.
Economic evaluation
The economic evaluation aims to assess overall cost-
effectiveness from the perspective of the health system
(NHS) and patients. It will consist of a within-trial cost
effectiveness analysis and a decision analytic cost effec-
tiveness model. The within-trial analysis will evaluate
the costs and outcomes of the patients recruited to
SWITCH for the follow-up of the trial. As with the pri-
mary analysis, the economic evaluation will be an
intention to treat analysis. The outcome used in the pri-
mary analysis will be the Quality Adjusted Life Year.
Using the NICE cost effectiveness threshold of 20,000
per QALY [81], we will convert costs and outcomes for
each patient on to the Net Benefit scale and use linear
regression analysis to estimate the expected Net Benefit
of the trial interventions compared to current practice
[82]. Analysis of uncertainty will be undertaken using
the non-parametric bootstrap, to characterise the uncer-
tainty in the estimates of Net Benefit.
A second analysis will synthesise the data from the
SWITCH trial with existing evidence to estimate the life-
time expected net benefit of the trial interventions com-
pared to current standard care. The perspective for this
analysis will be the same as for the within trial analysis.
In order to capture the switching nature of the treat-
ment pathways, we will construct patient level simula-
tion model, rather than the Markov cohort model, which
is frequently used for decision analytic cost effectiveness
analyses.
The primary modelled analyses will adopt the perspec-
tive of the NHS and Public Social Services. Secondary
analyses will adopt a broader perspective incorporating
carer quality of life and cost impacts, and productivity
costs.
Resource utilisation will be captured at each follow-up
visit. Personal expenditures related to the management
Figure 4 Schedule of events for subcutaneous biologic DMARDs (etanercept, adalimumab, certolizumab pegol, abatacept, golimumab).
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of RA, and time spent away from work by the patient
and carers will be collected using the Cost Diary, a vali-
dated questionnaire [79]. Unit costs will be taken from
routine national databases such as the British National
Formulary, the NHS Reference Costs and the Personal
Social Services Research Unit (PSSRU) costs of health
and social care [83]. Health-related quality of life will be
captured using the EQ-5D supplemented by the Health
Utilities Index. These data will be collected at baseline
and at each clinical follow-up. Parameter uncertainty will
be addressed through probabilistic sensitivity analysis.
For the within trial analysis this will be done using the
non-parametric bootstrap; for the decision analytic cost
effectiveness model this will be done using Monte Carlo
simulation.
Outputs from the analyses will be presented as Expected
Incremental Cost Effectiveness Ratios; Cost Effectiveness
Acceptability Frontiers, Expected Net Benefit [84] and Net
Benefit Probability Maps [85]. In addition to the primary
analyses, secondary analyses adopting different perspec-
tives, different utility measures and different approaches
to dealing with missing data will be presented. The final
set of analyses will present estimates of the global and
partial value of perfect information, to inform future
research.
Discussion
RA has a substantial individual and societal burden: symp-
toms impact heavily on patients' ability to perform daily
activities at home and ability to undertake work commit-
ments with subsequent cost to the NHS and state. It is
therefore important to treat this potentially disabling and
expensively managed condition effectively and with the
minimum of time delay.
There have been dramatic advances in the development
of effective drugs to treat RA and the use of TNFi has
transformed the lives of people suffering from RA. While
these drugs can be highly effective, universal response has
not been observed; indeed this is a common feature of all
the available and licensed bDMARDs (alternative TNFi, ri-
tuximab, abatacept and most recently, tocilizumab) likely
reflecting the complexity and heterogeneity of disease
pathogenesis. Some observational studies and preliminary
data from recent RCTs suggest both similar and better
efficacy amongst the available classes of bDMARD but
with no definitive investigation on the sequential biologic
treatment strategy: making it difficult to draw any firm
conclusion. Nevertheless, the National Institute for Health
and Care Excellence (NICE) has approved only the use of
rituximab following TNFi failure, thereby offering only one
option to patients. SWITCH is a direct comparison trial
that will facilitate the development of a rational treatment
algorithm and should enable more judicious and cost-
effective management. In addition, the exploratory analyses
in this trial may provide information on more effective tar-
geting of treatment regimens, as opposed to switching all
patients to only one available (and possible unsuccessful)
therapy (rituximab), leading to long-term cost-benefits and
improved patient outcomes.
Trial status
The first patient was enrolled into SWITCH on the 31st
July 2012 and recruitment is due to end in December 2016.
The study is being conducted in multiple NHS sites across
the UK, with a planned total of up to 50 sites. We expect to
report the main trial results in Autumn 2018. Ethical and
governance approval for this trial has been obtained from
the Leeds West Ethics Committee (ref 11/H1307/6) and
the Leeds Teaching Hospitals NHS Trust respectively.
The trial progress is monitored by an independent Data
Monitoring and Ethics Committee (DMEC) and Trial
Steering Committee (TSC).
Since opening, the trial has undergone a major trial re-
design. Our original target sample size was 870 patients, to
have 80% power for determining whether abatacept or
alternative TNFi were non-inferior to rituximab at 24 weeks
post randomisation in terms of achieving a DAS28 re-
duction of greater than 1.2 points without toxicity. The
corresponding non-inferiority margin was set at 12% and
assumed a response rate of 65% in the rituximab arm. The
original trial design was also powered for a definitive
sub-group analysis to determine if there is a differential
treatment response between seropositive and seronegative
patients Following challenges in recruiting patients and
securing site participation, as well as re-discussion of mea-
ningful endpoints, a decision was made to re-design the
trial by modifying the primary outcome measure from a
binary to a continuous outcome (which was also deemed
clinically relevant). This allowed a reduction in sample size
to 477 patients whilst still ensuring a trial of clinical rele-
vance. The previous planned definitive sub-group analysis is
now an exploratory analysis. The trial re-design was unani-
mously supported by the DMEC and the TSC, approved by
the funder and has received favourable ethical opinion.
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